First Line Chemotherapy for Advanced Cancer

• Status: Terminated
• Trial end date: 2016-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether albumine-bounded paclitaxel plus S-1 are effective in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel

Criteria

Inclusion Criteria:

• Inoperable locally advanced, recurrent, and/or metastatic adenocarcinoma of the stomach or gastro-esophageal junction

• Adult patients >=18 years of age

• Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-2;

• At least have one measurable disease(according to RECIST)

• Adequate bone marrow,renal and liver function

Exclusion Criteria:

• Previous chemotherapy for advanced/metastatic disease

• Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome